MET-Targeted Therapy | Clinical

Increased Attention on Testing for Oncogenic Drivers in NSCLC Advances the Promise of Precision Medicine

December 09, 2020

Identification of key oncogenic drivers and the development of targeted therapies with clinical activity in patients harboring actionable mutations have revolutionized the treatment paradigm in non–small cell lung cancer, redirecting attention toward advances in biomarker testing methodologies.

Safety, Pharmacokinetic Findings Are Revealed for MET Inhibitor TPX-0022

December 01, 2020

The MET inhibitor TPX-0022 was safe and well tolerated in a phase 1 dose-escalation study, SHIELD-1, involving patients with advanced solid tumors harboring MET alterations, according to results presented during the 32nd Molecular Targets and Cancer Therapeutics Symposium.

Heymach Discusses MET Exon 14 Skipping Mutations in NSCLC

November 03, 2020

During a Targeted Oncology Case Based Peer Perspective event, John V. Heymach, MD, PhD, discussed the testing methods for non–small cell lung cancer with MET exon 14 skipping mutations. The discussion was based on the case of a 48-year-old woman.

Crizotinib Activity in MET-Altered Non-Small Cell Lung Cancer Undetermined

October 29, 2020

While the remarkable activity of crizotinib as treatment of patients with ROS1 fusion-positive advanced non–small cell lung cancer was confirmed in a recent systemic review and meta-analysis, the efficacy of this small molecular inhibitor remains unknown in patients with MET-altered disease.

Tepotinib Granted Priority Review in MET Exon 14+ Metastatic NSCLC

August 25, 2020

The FDA accepted a New Drug Application for tepotinib and granted it priority review for the treatment of adult patients with metastatic non–small cell lung cancer who harbor a mutation that leads to mesenchymal-epithelial transition exon 14 skipping, as detected by an FDA-approved test.

Correlation Between ctDNA Clearance and PFS Improvement Demonstrated in EGFR+/MET+ NSCLC

June 23, 2020

MET amplifications are found in up to 10% of patients with EGFR-mutant NSCLC who progress on first- or second-generation EGFR TKIs and in up to 25% of those who progress on a third-generation EGFR TKIs, necessitating the need for treatment options in the population.